IBM (NYSE: IBM) was selected for its contributions to the EuResist research project for AIDS treatment as a Computerworld Honors Program Laureate for 2008. In addition to the Laureate Medal, EuResist also won the 21st Century Achievement award, establishing this technology contribution as top of its class among the Healthcare Laureates. Developed by IBM researchers in Haifa, Israel, the project's new technologies and mathematical models are providing a smarter and more efficient way to choose the best drugs and drug combinations for any given HIV genetic variant. EuResist is a powerful online system that helps doctors choose the treatment with the highest probability of halting virus replication and impairing evolution of drug resistance.
Although there have been tremendous leaps and bounds in the management of the virus that causes AIDS, HIV has the ability to develop resistance to any antiretroviral compound. This means that doctors need to continuously monitor and prescribe new therapies for the treatment to remain effective. Keeping HIV under control is dependant on choosing the right combination of drugs that work for the longest period of time.
EuResist is the first and only freely available data-driven computational method that predicts the success of a treatment regimen against any given HIV genotype, based not only on viral genotype information, but using smarter analytic technologies to take into account treatment response information from clinical practice. It is also the only system providing the global medical community with an estimate of activity for combination therapy, rather than for individual drugs.
Researchers behind the EU-funded EuResist project have developed new mathematical prediction models that not only take into account the patient's own history, but tap into the wealth of information that EuResist researchers have amassed. The recent expansion of the EuResist database to include information from more than 33,000 patients and 98,000 therapies, and 370,000 viral load measurements - makes it the world's biggest database centered on HIV resistance and clinical response information.
"EuResist has managed to create the largest clinically oriented antiretroviral drug resistance database in the world," explained Prof. Maurizio Zazzi, EuResist Scientific Coordinator and Professor of Microbiology at the University of Siena School of Medicine. "The ability to analyze clinical, laboratory and demographic data accumulated over the years significantly improves prediction of the right combination of drugs that works for the maximum amount of time." These innovations are being provided as a free tool that can help extend the lives of millions of people who are the victims of this killer disease.
The system's predictions are near 76% accurate, outperforming other commonly used HIV resistance prediction tools and also outperformed human experts in the field. To simulate real practice in HIV specialized care, the EVE (Engine versus Experts) study compared EuResist with 10 international experts confronted with 25 case histories, where all the clinical and virological information was available, EuResist's predictions outperformed nine out of ten human experts.
"The EuResist team feels both humbled and privileged by the opportunity to put good science and state-of-the-art technologies at the service of such an important and meaningful cause," noted Yardena Peres, researcher at the IBM Research Lab in Haifa and one of the leaders for the IBM contribution for the EuResist project.
Along with talent from the IBM Research Lab in Haifa, the brains behind the EuResist project come from the EuResist Network, a non-profit partnership of pharmaceutical companies, governmental institutions, and private companies, and its GEIE partners including a European Economic Interest Grouping composed of Karolinska Institute, Max Planck Institute, University of Siena, Informa s.r.l., University of Cologne.
Related news articles:
- IBM Healthcare's Profile
- FP6 Projects:EuResist
About the Computerworld Honors Program
Founded by International Data Group (IDG) in 1988, the Computerworld Honors Program is governed by the not-for-profit Computerworld Information Technology Awards Foundation. In its 21st year, Computerworld Honors is the longest running global program to honor individuals and organizations that use information technology to benefit society.
Each year, the program's Chairmen's Committee, a group of 100 Chairmen/CEOs of global technology companies, nominates individuals and organizations around the world whose visionary application of information technology promotes positive social and economic progress. Nominations are evaluated by an independent board of CIO-level judges who select Laureates, Finalists and award recipients, in 10 industry-related categories, to be honored at the Laureate Medal Ceremony. This year's ceremony and accompanying Gala Awards Evening will take place on June 1, 2009 at the Andrew W. Mellon Auditorium in Washington, D.C.
The technology achievements honored by this program are preserved and protected in national archives, and in over 350 universities, museums and research institutions throughout the world. Additional information about the program and a Global Archive of past Laureate case studies and oral histories can be found at the Computerworld Honors website: www.cwhonors.org.